Age

18–65

Sex

ALL

Healthy volunteers

Not accepted

Age: 18-65 years old.
Gender: Male and female.
Newly diagnosed colorectal cancer patients who are scheduled to receive capecitabine-based chemotherapy.
Eastern Cooperative Oncology Group (ECOG) performance status \< 2
Patients with adequate renal function (Sr. creatinine \< 1.2 mg/dl or eGFR ≥ 90 ml/min).
Patients with adequate hepatic function (Sr. bilirubin \< 1.2 mg/dl).

Pregnant and lactating females.
Patients with cardiovascular disease (congestive heart failure, cardiac arrhythmia, or coronary artery disease, …. etc.).
History of H-Pylori infection.
Patients with a known hypersensitivity to any of the used drugs.
Patients with any contraindication to any of the used drugs.

Possible Protective Effect of Celecoxib Against Capecitabine Induced Hand and Foot Syndrome in Patients With Colorectal Cancer